Search
Inhibrx Biosciences Inc
INBXAdd to Watchlist
82.050USD
-2.680-3.16%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Inhibrx Biosciences Inc is 8.00, ranking 171 out of 385 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
277.500
Target Price
+238.21%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Inhibrx Biosciences Inc
INBX
3
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Inhibrx Biosciences Inc's price target?
Analysts forecast that Inhibrx Biosciences Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 12.00.
How have Inhibrx Biosciences IncINBX's recent earnings per share performed?
The market expectation was USD -2.15, while Inhibrx Biosciences IncINBX's earnings per share (EPS) for the previous quarter was USD -2.11. EPS for the next quarter is expected at USD -2.39.
What is the analyst rating for Inhibrx Biosciences Inc?
Based on the ratings of Inhibrx Biosciences Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.